118 related articles for article (PubMed ID: 22383033)
1. Designer tridentate mucin 1 aptamer for targeted drug delivery.
Tan L; Gee Neoh K; Kang ET; Choe WS; Su X
J Pharm Sci; 2012 May; 101(5):1672-7. PubMed ID: 22383033
[TBL] [Abstract][Full Text] [Related]
2. PEGylated anti-MUC1 aptamer-doxorubicin complex for targeted drug delivery to MCF7 breast cancer cells.
Tan L; Neoh KG; Kang ET; Choe WS; Su X
Macromol Biosci; 2011 Oct; 11(10):1331-5. PubMed ID: 21818856
[TBL] [Abstract][Full Text] [Related]
3. Aptamer-guided DNA tetrahedron as a novel targeted drug delivery system for MUC1-expressing breast cancer cells in vitro.
Dai B; Hu Y; Duan J; Yang XD
Oncotarget; 2016 Jun; 7(25):38257-38269. PubMed ID: 27203221
[TBL] [Abstract][Full Text] [Related]
4. Multifunctional Bioconjugate for Cancer Cell-Targeted Theranostics.
Du W; Yuan Y; Wang L; Cui Y; Wang H; Xu H; Liang G
Bioconjug Chem; 2015 Dec; 26(12):2571-8. PubMed ID: 26580576
[TBL] [Abstract][Full Text] [Related]
5. Specific targeting delivery to MUC1 overexpressing tumors by albumin-chitosan nanoparticles conjugated to DNA aptamer.
Esfandyari-Manesh M; Mohammadi A; Atyabi F; Nabavi SM; Ebrahimi SM; Shahmoradi E; Varnamkhasti BS; Ghahremani MH; Dinarvand R
Int J Pharm; 2016 Dec; 515(1-2):607-615. PubMed ID: 27989825
[TBL] [Abstract][Full Text] [Related]
6. A novel MUC1 aptamer-modified PLGA-epirubicin-PβAE-antimir-21 nanocomplex platform for targeted co-delivery of anticancer agents in vitro and in vivo.
Bahreyni A; Alibolandi M; Ramezani M; Sarafan Sadeghi A; Abnous K; Taghdisi SM
Colloids Surf B Biointerfaces; 2019 Mar; 175():231-238. PubMed ID: 30537619
[TBL] [Abstract][Full Text] [Related]
7. Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro.
Yu C; Hu Y; Duan J; Yuan W; Wang C; Xu H; Yang XD
PLoS One; 2011; 6(9):e24077. PubMed ID: 21912664
[TBL] [Abstract][Full Text] [Related]
8. Novel MUC1 aptamer selectively delivers cytotoxic agent to cancer cells in vitro.
Hu Y; Duan J; Zhan Q; Wang F; Lu X; Yang XD
PLoS One; 2012; 7(2):e31970. PubMed ID: 22384115
[TBL] [Abstract][Full Text] [Related]
9. Targeted delivery of doxorubicin using a colorectal cancer-specific ssDNA aptamer.
Li W; Chen H; Yu M; Fang J
Anat Rec (Hoboken); 2014 Dec; 297(12):2280-8. PubMed ID: 25044297
[TBL] [Abstract][Full Text] [Related]
10. Aptamer decorated hyaluronan/chitosan nanoparticles for targeted delivery of 5-fluorouracil to MUC1 overexpressing adenocarcinomas.
Ghasemi Z; Dinarvand R; Mottaghitalab F; Esfandyari-Manesh M; Sayari E; Atyabi F
Carbohydr Polym; 2015 May; 121():190-8. PubMed ID: 25659689
[TBL] [Abstract][Full Text] [Related]
11. 5TR1 aptamer-PEGylated liposomal doxorubicin enhances cellular uptake and suppresses tumour growth by targeting MUC1 on the surface of cancer cells.
Moosavian SA; Abnous K; Akhtari J; Arabi L; Gholamzade Dewin A; Jafari M
Artif Cells Nanomed Biotechnol; 2018 Dec; 46(8):2054-2065. PubMed ID: 29205059
[TBL] [Abstract][Full Text] [Related]
12. A dual-targeting DNA tetrahedron nanocarrier for breast cancer cell imaging and drug delivery.
Liu X; Wu L; Wang L; Jiang W
Talanta; 2018 Mar; 179():356-363. PubMed ID: 29310244
[TBL] [Abstract][Full Text] [Related]
13. Microenvironmental Control of MUC1 Aptamer-Guided Acid-Labile Nanoconjugate within Injectable Microporous Hydrogels.
Xu C; Han X; Jiang Y; Yuan S; Wu Z; Wu Z; Qi X
Bioconjug Chem; 2017 Oct; 28(10):2530-2537. PubMed ID: 28949511
[TBL] [Abstract][Full Text] [Related]
14. The application of aptamer 5TR1 in triple negative breast cancer target therapy.
Luo S; Wang S; Luo N; Chen F; Hu C; Zhang K
J Cell Biochem; 2018 Jan; 119(1):896-908. PubMed ID: 28671278
[TBL] [Abstract][Full Text] [Related]
15. Smart aptamer-modified calcium carbonate nanoparticles for controlled release and targeted delivery of epirubicin and melittin into cancer cells in vitro and in vivo.
Yazdian-Robati R; Arab A; Ramezani M; Rafatpanah H; Bahreyni A; Nabavinia MS; Abnous K; Taghdisi SM
Drug Dev Ind Pharm; 2019 Apr; 45(4):603-610. PubMed ID: 30633594
[TBL] [Abstract][Full Text] [Related]
16. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer.
Bagalkot V; Zhang L; Levy-Nissenbaum E; Jon S; Kantoff PW; Langer R; Farokhzad OC
Nano Lett; 2007 Oct; 7(10):3065-70. PubMed ID: 17854227
[TBL] [Abstract][Full Text] [Related]
17. One-Step Self-Assembly of Multifunctional DNA Nanohydrogels: An Enhanced and Harmless Strategy for Guiding Combined Antitumor Therapy.
Wei H; Zhao Z; Wang Y; Zou J; Lin Q; Duan Y
ACS Appl Mater Interfaces; 2019 Dec; 11(50):46479-46489. PubMed ID: 31747745
[TBL] [Abstract][Full Text] [Related]
18. Targeted and ultrasound-triggered drug delivery using liposomes co-modified with cancer cell-targeting aptamers and a thermosensitive polymer.
Ninomiya K; Yamashita T; Kawabata S; Shimizu N
Ultrason Sonochem; 2014 Jul; 21(4):1482-8. PubMed ID: 24418100
[TBL] [Abstract][Full Text] [Related]
19. Anti-MUC1 Aptamer/Negatively Charged Amino Acid Dendrimer Conjugates for Targeted Delivery to Human Lung Adenocarcinoma A549 Cells.
Masuda M; Kawakami S; Wijagkanalan W; Suga T; Fuchigami Y; Yamashita F; Hashida M
Biol Pharm Bull; 2016; 39(10):1734-1738. PubMed ID: 27725454
[TBL] [Abstract][Full Text] [Related]
20. Release of photoactivatable drugs from plasmonic nanoparticles for targeted cancer therapy.
Luo YL; Shiao YS; Huang YF
ACS Nano; 2011 Oct; 5(10):7796-804. PubMed ID: 21942498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
